

Amendments to the Claims

Claim 1 (Cancelled).

Claim 2 (Currently amended): The method of claim 9-10 wherein the S-alkylthiol is selected from the group consisting of S-ethylcysteine, S-methylcysteine, S-methylcysteamine, S-ethylcysteamine, S-ethylglutathione, S-methylglutathione, S-methylcoenzyme A, and S-ethylcoenzyme A.

Claim 3 (Currently amended): The method of claim 9-10 wherein the S-alkylthiol is selected from the group consisting of S-ethyl-L-cysteine, S-methyl-L-cysteine, S-ethylglutathione, S-methylglutathione, S-methylcysteamine, S-ethylcysteamine, S-methylcoenzyme A and S-ethylcoenzyme A.

Claim 4 (Currently amended): The method of claim 9-10 wherein the S-alkylthiol is a pharmaceutically acceptable salt form.

Claim 5 (Previously presented): The method of claim 2 wherein the S-alkylthiol is a pharmaceutically effective salt form.

Claim 6 (Previously presented): The method of claim 3 wherein the S-alkylthiol is a pharmaceutically acceptable salt form.

Claim 7 (Currently amended): The method of claim 9-10 wherein administration is intravenously.

Claim 8 (Currently amended): The method of claim 9-10 wherein the dose ranges from about 100 mg to about 10 g.

Claim 9 (Cancelled).

Claim 10 (New): A method of counter acting the overproduction of nitric oxide which often occurs in hypotension and shock, consisting essentially of:
administering to a patient a therapeutically effective amount of an S-alkylthiol as an antagonist of S-nitrosothiols.